Intel stock spikes after report of possible US government stake
PASADENA, Calif. - Arrowhead Pharmaceuticals, Inc. (NASDAQ: NASDAQ:ARWR), a $2.39 billion market cap biotechnology company, has expanded its We’ll Get There Soon campaign by launching a new website and a white paper on Rare Disease Day, aimed at supporting individuals with Familial Chylomicronemia Syndrome (FCS) and extremely high triglycerides. The website, www.LowerMyTGs.com, offers educational materials, patient stories, and community engagement tools. According to InvestingPro data, while the company’s stock has faced challenges with a 44% decline over the past year, analysts maintain a bullish outlook with multiple upward earnings revisions for the upcoming period.
FCS is an ultra-rare genetic disorder that results in the body’s inability to process triglycerides properly, leading to levels that can exceed 880 mg/dL and pose a risk of acute pancreatitis. The Spotlight on FCS white paper, developed in collaboration with the FCS Foundation, Action (WA:ACT) FCS, and FH Europe Foundation, shares patient experiences to raise awareness and address the challenges faced by those with the condition. InvestingPro analysis reveals that despite current losses, the company maintains a strong liquidity position with a current ratio of 6.09, providing financial stability to support such initiatives.
The website and white paper are part of Arrowhead’s commitment to the FCS community, providing a platform for education and connection. Lindsey Sutton, co-founder of the FCS Foundation, emphasized the importance of the white paper in giving a voice to the FCS community and illuminating the unmet needs of patients.
Andy Davis, Senior Vice President, Global Cardiometabolic Franchise at Arrowhead, reiterated the company’s dedication to advancing RNAi-based therapies for challenging diseases and supporting the FCS community through these new resources.
FCS, often caused by various monogenic mutations, can lead to severe health issues including pancreatitis, abdominal pain, diabetes, and cognitive problems. Currently, treatment options for FCS are limited, highlighting the need for the resources provided by Arrowhead’s campaign.
The FCS Foundation, established in 2016, serves as a resource and advocacy group for the FCS community, hosting annual meetings and working to advance future treatments.
Arrowhead Pharmaceuticals specializes in developing RNAi-based therapeutics to silence genes causing intractable diseases. For more information on their work and RNA interference technology, visit www.arrowheadpharma.com.
This expansion of the We’ll Get There Soon campaign and the launch of the patient resources are based on a press release statement from Arrowhead Pharmaceuticals.
In other recent news, Arrowhead Pharmaceuticals reported a significant earnings miss for Q1 FY2025, with earnings per share at -$1.39 compared to the forecasted -$0.39. Revenue also fell short, totaling $2.5 million against a projected $74.42 million. Despite these financial setbacks, Arrowhead Pharmaceuticals secured a substantial $1.375 billion licensing deal with Sarepta Therapeutics (NASDAQ:SRPT), providing a strong cash position projected to extend into 2028. Following the deal, RBC Capital maintained an Outperform rating with a $42 price target, while Chardan Capital Markets reiterated a Buy rating with a $60 target, reflecting confidence in Arrowhead’s clinical development strategy.
Arrowhead is advancing multiple clinical trials, including Phase III studies for plozasiran targeting severe hypertriglyceridemia (SHTG), with full enrollment expected within the year. The company also plans to initiate a Phase III trial for ANG3 aimed at treating homozygous familial hypercholesterolemia (HoFH). BofA Securities adjusted Arrowhead’s price target to $41 from $46, while maintaining a Buy rating, citing strategic decisions impacting the company’s valuation model. These developments underscore Arrowhead’s focus on its cardiometabolic portfolio, supported by the recent financial boost from the Sarepta deal.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.